New sequencing approach resolves the genetic complexity of a rare Mendelian condition MENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leader in high-quality, long-read sequencing,…
MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Global Institute for Food Security (GIFS)…
MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center…
Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK,…
MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery,…
Berry Genomics will leverage PacBio Vega System to develop long-read sequencing-based solutions for patients in China and other countries MENLO PARK, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ:…
MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the…
MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the…
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million…
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negotiated…
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory Translations: Japanese | Chinese | Korean MENLO PARK, Calif., Nov. 06, 2024 (GLOBE…
New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics Translations: Chinese | …
MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read…
Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology, accelerating breakthroughs in cancer genomics across Asia SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer…
MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results…
If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.